A Test in Focus
A new epilepsy autoimmune evaluation is now available. View this post to learn what providers should know about autoimmune epilepsy, our testing approach, as well as interpretation, follow-up, and additional considerations once the test has been ordered.
A new Trichomonas vaginalis assay is now available. This test should be ordered in individuals suspected to be infected with Trichomonas vaginalis. View this post to watch a short three-minute video overview from Bobbi Pritt, M.D. and to view new test utilization pearls.
The new CALR Mutation Analysis, Myeloproliferative Neoplasm (MPN) assay is now available to the Mayo Clinic practice and Mayo Medical Laboratories clients. This test should be ordered on patients with clinical suspicion of essential thrombocythemia or primary myelofibrosis.
This new gene panel cancer test helps tailor therapies to the individual patient based on the unique genomic signature of the patient’s tumor. This test scans specific regions in 50 genes known to affect tumor growth and response to therapies. The test is now available to Mayo Clinic patients and to providers worldwide through Mayo Medical Laboratories.
This new Mayo Clinic assay provides clinicians an accurate measurement of serum thyroglobulin in patients with known or suspected anti-thyroglobulin autoantibodies or heterophilic antibodies. View a quick overview of the test’s details and a five-minute video interview with Dr. Stefan Grebe.
This new Mayo Clinic assay detects the 14 high-risk HPV types, and if present, provides specific genotype results for HPV-16 and/or HPV-18.
David Murray, M.D., Ph.D., provides a brief overview of the new Alpha-1-Antitrypsin Proteotype S/Z by LC-MS/MS, Serum test now available from Mayo Medical Laboratories. This test should be ordered for individuals suspected of A1A deficiency and can be used for diagnosis and identification of a specific proteotype to determine prognosis.
Robin Patel, M.D., chair of Mayo Clinic’s Division of Microbiology, provides a three-minute overview of a new test for Coxiella burnetii, the causative agent of Q fever. The real-time PCR test rapidly detects Coxiella burnetii DNA in clinical specimens by targeting a sequence of the shikimate dehydrogenase gene (aroE) unique to Coxiella burnetii.
Melanocytic tumors arising in the skin can present a significant diagnostic challenge. While many lesions can be easily classified as benign nevi or malignant melanoma based on histologic features alone, there is a significant subset of lesions that cannot be clearly defined as either benign or malignant. To aid in diagnosis and differentiation of malignant from benign melanocytic lesions, a (FISH)-based test panel has been developed.